目的:通过[18F]FDGPET/MR评估基线和抗逆转录病毒治疗(ART)后1年HIV诱导炎症的生物标志物。
方法:前瞻性研究,14名患者,新诊断为HIV阳性,无症状。[18F]FDGPET/MRI(PET/MR-3.0T,老天.GE)进行了全身和心脏检查,基线和ART后1年。定性血管评估(肝脏参考)。整个身体的定量评估(SUVmax)。16个心肌节段的T1和T2值估量。
结果:基线CMR显示3(21.4%)LVEF降低,战后正常化。排除纤维化(T1),在基线或TAR后没有心肌水肿(T2)的迹象。四个(28.6%)显示基线血管[18F]FDG摄取,两个在升胸主动脉中,两个在升和降胸主动脉中,战后正常化。所有(100%)显示基底淋巴结活动;同上(n:14)和膈肌(n:13),颈外侧(n:14)和腹股沟(n:13),区域数量可变(9例患者>6;64.3%)。艺术后,7例患者(50%)显示分辨率,其他7例延长减少(0例患者>5):7例超(100%)和2例膈肌(28.6%),5在腋窝和2在腹股沟。所有(100%)在ART后都有持续的基底腺样体摄取,9(64.3%)脾全部在ART后消退,7(50.5%)胃,持续3后ART。
结论:通过[18F]FDGPET/MR的心血管生物标志物显示基线28.6%的大血管活动患者和21.4%的低LVEF患者,标准化后的艺术。炎症/免疫生物标志物在100%的淋巴结中显示基线活性,100%腺样体,64.3%脾和50.5%胃。TAR后淋巴结减少50%,0%腺样体,100%脾和57.1%胃。
OBJECTIVE: To assess by [18F]FDG PET/MR the biomarkers of HIV-induced inflammation at baseline and 1 year post-antiretroviral therapy (ART).
METHODS: Prospective study, 14 patients, newly diagnosed HIV-positive, asymptomatic. [18F]FDG PET/MRI (PET/MR-3.0T, Signa.GE) whole body and heart was performed, baseline and 1 year post-ART. Qualitative vascular assessment (hepatic reference). Quantitative assessment (SUVmax) of the whole body. T1 and T2 value estimation in 16 myocardial segments.
RESULTS: Baseline CMR showed in 3 (21.4%) a decreased LVEF, normalising post-TAR. Fibrosis was ruled out (T1), with no signs of myocardial oedema (T2) at baseline or post-TAR. Four (28.6%) showed baseline vascular [18F]FDG uptake, two in ascending thoracic aorta and two in ascending and descending thoracic aorta, normalising post-TAR. All (100%) showed basal lymph-nodes activity; supra (n:14) and infradiaphragmatic (n:13), laterocervical (n:14) and inguinal (n:13), with variable number of territories (9 patients >6;64.3%). Post-ART, 7 patients (50%) showed resolution and the other 7 reduction in extension (0 patients >5): 7 supra (100%) and 2 infradiaphragmatic (28.6%), 5 in the axilla and 2 in the groin. All (100%) had persistent basal adenoid uptake post-ART, 9 (64.3%) splenic all resolved post-ART and 7 (50.5%) gastric, persistent 3 post-ART.
CONCLUSIONS: Cardiovascular biomarkers by [18F]FDG PET/MR have shown baseline 28.6% of patients with large vessel activity and 21.4% with low LVEF, normalising post-ART. Inflammatory/immune biomarkers showed baseline activity in 100% of lymph-nodes, 100% adenoids, 64.3% splenic and 50.5% gastric. Post-TAR the reduction was 50% lymph-nodes, 0% adenoid, 100% splenic and 57.1% gastric.